Superior Survival Benefit With Ramucirumab Plus Pembrolizumab Observed in ICI-Resistant NSCLC
June 3rd 2022The addition of ramucirumab to pembrolizumab elicited significant response among patients with advanced non–small cell lung cancer who experienced disease progression following treatment with PD-1/PD-L1 inhibitors and platinum-based doublet chemotherapy.
Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC
June 3rd 2022Adagrasib led to early onset and deep responses translating to encouraging survival as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer, according to results from cohort A of the phase 1/2 KRYSTAL-1 trial.
Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma
Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.
Ibrutinib Plus Bendamustine and Rituximab Shows PFS Benefit in Older Patients with MCL
June 3rd 2022Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.
Black Patients Less Likely to Participate on Clinical Trials in Breast Cancer
May 26th 2022Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.
Frontline Encorafenib/Cetuximab Plus or Minus Chemo Is Under Evaluation for BRAF V600E–Mutant mCRC
The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.
Dr. Chandarlapaty on Responses to Amcenestrant/Palbociclib in ER+/HER2- Metastatic Breast Cancer
June 12th 2021Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.
Week 24 Transfusion Independence With Momelotinib Is Associated With Improved OS in Myelofibrosis
June 10th 2021Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.
Regorafenib/Pembrolizumab Combination Yields Encouraging Results in Advanced HCC
June 10th 2021The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.
Frontline Belzutifan Showcases Significant Clinical Activity in VHL-Associated RCC
The hypoxia-inducible factor-2 alpha inhibitor belzutifan maintained clinical efficacy with further follow-up in patients with Von-Hippel Lindau–associated renal cell carcinoma, as well as other VHL-associated neoplasms.
Lenvatinib/Pembrolizumab Yields Survival Benefit in Advanced RCC Across IMDC Risk Groups
June 9th 2021The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.
Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC
June 9th 2021The combination of pembrolizumab and cabozantinib induced a response in more than half of patients with metastatic renal cell carcinoma at the recommended phase 2 dose with a manageable safety profile, meeting the primary end point of a phase 1/2 trial.
Addition of Abiraterone to ADT plus Docetaxel Yields Improvement in rPFS in De Novo mCSPC
June 9th 2021Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.
Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma
June 8th 2021The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Subsequent Therapy May Impact OS Outcomes With Frontline Lenvatinib/Everolimus in RCC
June 8th 2021Subsequent systemic therapies were found to impact overall survival outcomes with lenvatinib plus everolimus versus sunitinib in patients with advanced renal cell carcinoma who received treatment in the phase 3 CLEAR trial.